Stakeholder Perspectives: Pulmonary Arterial Hypertension - A small market gets big attention
Report
Stakeholder Perspectives: Pulmonary Arterial Hypertension - A small market gets big attention is a marketing resource from Datamonitor, a leading provider of online data, analytic and forecasting platforms for key vertical sectors.
Datamonitor expects the global pulmonary arterial hypertension (PAH) market to grow from $636m in 2004 to just over $2 billion by 2014, as new product and formulation launches in the US and a healthy late-stage pipeline drive sales growth. With this increased interest, combined with increased awareness and R&D activity, treatment for this orphan disease is set to enter a new era
Scope
Comprehensive analysis of the attractiveness of the PAH market based on epidemiology, unmet needs, R&D activity and potential revenue
Analysis of clinical trial data and market potential of the recently launched PAH specific therapies and compounds in late stage development
Detailed comparative analysis of all PAH specific compounds in terms of efficacy, drug delivery, target audience and cost
In-depth profiles of current treatments, including PAH specific and non-PAH specific compounds
Highlights
PAH is a rare condition with an estimated 146,000 sufferers across the US, EU and Japan. However, despite this low patient population, this market has attracted R&D investment due to the high unmet needs and high treatment values per patient
Despite low patient numbers, it is estimated that up to 75% of these patients are not recognized and treated with therapy, creating significant room for growth in the number of patients treated with PAH therapies over the next decade
Actelion's Tracleer, the first oral therapy approved by the FDA in 2001, will come under significant competitive pressure over the next three years. With approval for Encysive's Thelin expected in March 2006 and Myogen's ambrisentan expected to launch in 2007, an intense marketing battle is expected as each company fights for market share
Reasons to Purchase
Assess the attractiveness of the PAH market for R&D investment and/or in-licensing activity
Gain insight into the current challenges and commercial opportunities associated with this devastating disease
Access key opinion leader views on the relative merits and weaknesses of current and future treatments for PAH, and the unmet needs therein
Stakeholder Perspectives: Pulmonary Arterial Hypertension - A small market gets big attention is a marketing resource from Datamonitor, a leading provider of online data, analytic and forecasting platforms for key vertical sectors.